Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants-Reference-Cited by-同舟云学术

Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants

Published:2021-11-23 Issue:24 Volume:95 Page:
ISSN:0022-538X
Container-title:Journal of Virology
language:en
Short-container-title:J Virol

Author:

Acharya Arpan¹,Pandey Kabita¹,Thurman Michellie¹,Klug Elizabeth¹,Trivedi Jay¹,Sharma Kalicharan²,Lorson Christian L.³⁴,Singh Kamal³⁴⁵,Byrareddy Siddappa N.¹⁵⁶⁷^ORCID

Affiliation:

1. Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska, USA

2. Delhi Pharmaceutical Sciences and Research University, New Delhi, India

3. Department of Veterinary Pathobiology, University of Missouri, Columbia, Missouri, USA

4. Bond Life Sciences Center, University of Missouri, Columbia, Missouri, USA

5. Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden

6. Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, Nebraska, USA

7. Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska, USA

Abstract

The ongoing coronavirus infectious disease 2019 (COVID-19) pandemic is caused by a novel coronavirus named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). More than 207 million people have been infected globally, and 4.3 million have died due to this viral outbreak.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Virology,Insect Science,Immunology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/JVI.01437-21

Reference63 articles.

1. A novel coronavirus outbreak of global health concern

2. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies

3. The proximal origin of SARS-CoV-2